Asco 2023 movers – maintaining the momentum
Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.
Asco 2023 – Roche sees Morpheus and takes the red pill
The company’s Tigit data are strong enough for a phase 3 trial to be launched, Asco learns.
Asco 2023 preview – Tigit lives again
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
Iteos – and GSK – keep the faith
With Tigit out of favour Belgium’s Iteos reckons it could have the best possible PD-(L)1 combo, but does GSK share its optimism?
Biotech heads towards big catalysts
The second quarter promises big data reveals for Fibrogen, Travere, Argenx and Bavarian Nordic.
Three Tigit players look to surprise in 2023
But two have already disappointed, and the third has shown little to suggest a positive outcome.
A success for Tigit? Not quite
The Arc-7 trial might be a numerical success, but Roche’s experience will weigh heavy.